- Home
- BVS vs SVRA Comparison
BVS vs SVRA Comparison
Compare BVS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVS | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.6M | 1.1B |
| IPO Year | 2016 | 2009 |
Fundamental Metrics
Financial Performance| Metric | BVS | SVRA |
|---|---|---|
| Price | $13.45 | $5.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $17.60 | $10.94 |
| AVG Volume (30 Days) | 408.8K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $6.46 | N/A |
| Revenue Next Year | $6.74 | $3,963.52 |
| P/E Ratio | $26.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.37 | $3.34 |
| 52 Week High | $15.89 | $7.01 |
Technical Indicators
Market Signals| Indicator | BVS | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 45.29 |
| Support Level | $13.44 | $5.16 |
| Resistance Level | $14.71 | $5.49 |
| Average True Range (ATR) | 0.44 | 0.22 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 75.14 | 45.11 |
Price Performance
Historical ComparisonAbout BVS Bioventus Inc.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).